prostate cancer

Studies reveal drop in PCa treatment, rise in metastatic diseaseFindings from two new studies provide insight on the impact of changing recommendations for prostate cancer screening and management.
Bone metastases Tx: 12-week dosing interval appears feasibleResults of a 2-year clinical trial support switching to a less frequent administration schedule when using zoledronic acid (Zometa) to prevent skeletal-related events in men with prostate cancer.
How will the ProtecT study affect your care of PCa patients?
Top 10 prostate cancer articles of 2016These are Urology Times' most-read prostate cancer articles of 2016.
Study examines link between inflammation, prostate CaResearchers at UCLA have discovered a previously unrecognized type of progenitor cell in inflamed areas of the prostate that have the ability to initiate cancer in response to genetic changes.
Few prostate Ca patients with BCR develop metastasisFewer than 20% of patients with biochemical recurrence after radical prostatectomy develop metastasis, and a smaller proportion die as a result of prostate cancer.
Is 1.5 the new magic number for PSA screening?A new approach to prostate cancer screening has been proposed by investigators who claim the idea of informed decision-making by primary care physicians is not working when it comes to PSA testing.
New Products: Test launched to improve prostate biopsy decision processOther new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.
Delay from biopsy to RP: Who is at risk of recurrence?The risk of prostate cancer relapse after radical prostatectomy increases with lengthening delay between diagnosis and surgery. The impact, however, is significant only in high-risk patients, and even in those men, there may be a window of up to 12 months during which it may be relatively safe to postpone surgery, reported researchers from Milan, Italy.
There’s something about PSA: Ben Stiller fights the good fightUrologist Henry Rosevear, MD, discusses actor Ben Stiller's recent blog post that credits PSA tests for saving his life after he was diagnosed with prostate cancer and the urologic community's surprising reaction to the article.